Treatment of prostate cancer with a combination of abiraterone acetate, niraparib tosylate monohydrate and prednisone
AssigneeJanssen Pharmaceutica NV
InventorsThomas Ronald A. Quinten, Urbain Alfons C. Delaet, Philip Erna H. Heyns, Tatiana Marcozzi, Johny Bertels, Katrien Luyten, Kaustubh Ramesh Tambwekar, Angela Lopez-Gitlitz, Paul J. A. Hartman Kok
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.
Claims18
A method for the treatment of prostate cancer in a male human patient, said method comprising administering to the patient an effective amount of a pharmaceutical formulation comprising abiraterone acetate and niraparib tosylate monohydrate, plus prednisone, wherein the patient has received or continues with gonadotropin releasing hormone agonists (GnRHa) therapy, or has undergone bilateral orchiectomy, prior to the treatment with the pharmaceutical formulation, plus prednisone.
A method for the treatment of mCRPC, with or without DNA-repair gene defects (DRD) or HRD in a male human patient, said method comprising administering to the patient an effective amount of a pharmaceutical formulation comprising abiraterone acetate and niraparib tosylate monohydrate, plus prednisone, wherein the mCRPC is also with cyclin dependent kinase 12 (CDK12) pathogenic alterations.
A method for the treatment of mCRPC, with or without DNA-repair gene defects (DRD) or HRD in a male human patient, said method comprising administering to the patient an effective amount of a pharmaceutical formulation comprising abiraterone acetate and niraparib tosylate monohydrate, plus prednisone, wherein the patient continues with gonadotropin releasing hormone agonists (GnRHa) therapy during the treatment with the pharmaceutical formulation plus prednisone, if not surgically castrated.
A method for the treatment of mCRPC, with or without DNA-repair gene defects (DRD) or HRD in a male human patient, said method comprising administering to the patient an effective amount of a pharmaceutical formulation comprising abiraterone acetate and niraparib tosylate monohydrate, plus prednisone, wherein the patient continues with gonadotropin releasing hormone agonists (GnRHa) therapy during the treatment with the pharmaceutical formulation plus prednisone, if not surgically castrated, and wherein the patient has been exposed to anti-androgens selected from nilutamide, flutamide, bicalutamide, enzalutamide, apalutamide, darolutamide, and abiraterone acetate;
- prior to the treatment with the pharmaceutical formulation plus prednisone.
A method for the treatment of mCRPC, with or without DNA-repair gene defects (DRD) or HRD in a male human patient, said method comprising administering to the patient an effective amount of a pharmaceutical formulation comprising abiraterone acetate and niraparib tosylate monohydrate, plus prednisone, wherein the patient has been exposed to anti-androgens selected from nilutamide, flutamide, bicalutamide, enzalutamide, apalutamide, darolutamide, and abiraterone acetate;
- prior to the treatment with the pharmaceutical formulation plus prednisone, wherein said anti-androgens are washed-out prior to the treatment with the pharmaceutical formulation plus prednisone.
Dependencies are inferred from the claim text.